SCHEMBL12295654

SCHEMBL12295654

O=C(NOC1CCCCO1)c1cnc(N2CCN(C(=O)OCC3c4ccccc4-c4ccccc43)CC2)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
PTPN11 Q06124 2/20 0.38
ALDH1A1 P00352 4/20 0.37
TSHR P16473 3/20 0.37
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 2/20 0.37
P2RX3 P56373 1/20 0.36
TGFBR1 P36897 1/20 0.35
POLB P06746 1/20 0.35
DGAT2 Q96PD7 2/20 0.34
HDAC1 Q13547 2/20 0.34
GSTP1 P09211 1/20 0.34
GSTM2 P28161 1/20 0.34
P2RY12 Q9H244 1/20 0.34
HPGD P15428 1/20 0.34
F10 P00742 1/20 0.34
KCNH2 Q12809 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12295616 0.90 HDAC1 (0.45) ALDH1A1KDM4EHDAC1P2RY12HPGD
SCHEMBL9883402 0.87 CHRM4 (0.38) P2RX3DGAT2HDAC1GSTP1GSTM2
SCHEMBL15344312 0.86 HDAC1 (0.48) PTPN11HDAC1HDAC3HDAC2HDAC6
SCHEMBL10097871 0.81 HDAC3 (0.47) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL15341328 0.80 KDM4E (0.42) MAPTALDH1A1TSHRKDM4EHSD17B10
SCHEMBL5503694 0.79 ALDH1A1 (0.40) PTPN11ALDH1A1TSHRKDM4EHSD17B10
SCHEMBL17897327 0.79 KMT2A (0.38) P2RX3TGFBR1POLBGSTP1GSTM2
SCHEMBL13535015 0.79 KDM4E (0.42) PTPN11ALDH1A1TSHRKDM4EHSD17B10
SCHEMBL12295653 0.78 MAPT (0.46) MAPTPTPN11ALDH1A1TSHRKDM4E
SCHEMBL15341327 0.78 ALDH1A1 (0.42) MAPTPTPN11ALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426416-B2 Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA, N.V. (BE) 2013-04-23 US disclosed
US-20110237585-A1 SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2011-09-29 US disclosed
US-7947830-B2 Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA N.V. (BE) 2011-05-24 US disclosed
US-7947830-B2 Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA N.V. (BE) 2011-05-24 US disclosed
US-7888360-B2 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase JANSSEN PHARMACEUTICA N.V. (BE) 2011-02-15 US disclosed
US-7884105-B2 2-(N'-2-amino-3,4-dioxocyclobutenyl)-N-piperazinyl)-pyrimidine-5-hydroxamic acid derivatives; antiproliferative, anticarcinogenic, and antitumor agents; psoriasis; skin, respiratory system, psychological, and genetic disorders; transplant rejection; Alzheimer's and Parkinson's disease; vision defects JANSSEN PHARMACEUTICA, N.V. (BE) 2011-02-08 US disclosed
US-20090036463-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-02-05 US disclosed
US-20080255140-A1 Squaric Acid Derivatives as Inhibitors of Histone Deacetylase JANSSEN PHARMACEUTICA, N.V. (BE) 2008-10-16 US disclosed
US-20070135424-A1 SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN-CILAG (BE) 2007-06-14 US disclosed
US-20070135424-A1 SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN-CILAG (BE) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036463-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC3 MAPT 3260/4885PTPN11 3323/4885ALDH1A1 517/4885
US-20080255140-A1 Squaric Acid Derivatives as Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 MAPT 3262/4885PTPN11 4268/4885ALDH1A1 239/4885
US-20070135424-A1 SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC3, HDAC2 MAPT 3052/4885PTPN11 3770/4885ALDH1A1 399/4885
US-20110237585-A1 SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC3, HDAC2 MAPT 3052/4885PTPN11 3770/4885ALDH1A1 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.